比 玛卢单抗
单克 | |
---|---|
种类 | ? |
ACVR2B | |
其他 | BYM338 |
ATC碼 |
|
识别 | |
CAS | 1356922-05-8 |
ChemSpider |
|
UNII | |
KEGG | |
C6306H9732N1684O1990S46 | |
142,451.78 g·mol−1 |
研 发历史 [编辑]
2013
2014
2016
参考 资料[编辑]
- ^ Garito T, Zakaria M, Papanicolaou DA, Li Y, Pinot P, Petricoul O, et al. Effects of bimagrumab, an activin receptor type II inhibitor, on pituitary neurohormonal axes. Clinical Endocrinology. June 2018, 88 (6): 908–919. PMID 29566437. S2CID 5019650. doi:10.1111/cen.13601.
- ^ 2.0 2.1 GlobalData Healthcare. Versanis' bimagrumab, first-in-class obesity therapy, enters Phase IIb of development. Pharmaceutical Technology. 2023-01-17 [2023-05-27]. (
原始 内容 存 档于2023-11-20) (美国 英 语). - ^ Novartis receives FDA breakthrough therapy designation for BYM338 (bimagrumab) for sporadic inclusion body myositis (sIBM). Novartis AG. 23 August 2013 [20 August 2013]. (
原始 内容 存 档于19 February 2014). - ^ Amato AA, Sivakumar K, Goyal N, David WS, Salajegheh M, Praestgaard J, et al. Treatment of sporadic inclusion body myositis with bimagrumab. Neurology. December 2014, 83 (24): 2239–2246. PMC 4277670
. PMID 25381300. doi:10.1212/WNL.0000000000001070.
- ^ Novartis: Planned filings 2015 to >=2019 (PDF). Novartis Investor Presentation. 27 January 2015 [27 May 2015]. (
原始 内容 (PDF)存 档于7 February 2015). - ^ Carroll J. Novartis' 'breakthrough' muscle drug bimagrumab flunks a late-stage trial. Fierce Biotech. 21 April 2016 [2023-12-04]. (
原始 内容 存 档于2023-12-04). - ^ Medication shows promise for weight loss in patients with obesity, diabetes. EurekAlert!. [2021-01-20]. (
原始 内容 存 档于2021-04-08) (英 语).
|